Long-term myocardial fibrosis and cardiac remodeling can increase the occurrence of malignant arrhythmias.[53] After entering the human body, valsartan inhibits the actions of angiotensin II (Ang II) by antagonizing the AT1 receptor, thus reducing blood pressure, reversing cardiac remodeling, and playing a therapeutic role in heart failure.[54] The aforementioned studies have shown that RAAS activation promotes ventricular fibrosis. Here, AGT is linked to Myocardial fibrosis.